Basic Information
| LncRNA/CircRNA Name | TATDN1 |
| Synonyms | TATDN1, CDA11 |
| Region | GRCh38_8:124488485-124539458 |
| Ensemble | ENSG00000147687 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | Microarray, qPCR, RNAi, Western blot, Flow cytometry assay etc. |
| Sample | NSCLC tissues, cell lines (95D, 95C) |
| Expression Pattern | up-regulated |
| Function Description | We found that TATDN1 (Homo sapiens TatD DNase domain containing 1, TATDN1), one of LncRNAs, was highly expressed in 95D cells and NSCLC tumor tissues compared to 95C cells. Knockdown of TATDN1-1 by shRNA significantly inhibited cell proliferation, adhesion, migration and invasion in 95D cells. Further mechanism study showed that TATDN1 knockdown suppressed the expression of E-cadherin, HER2, B-catenin and Ezrin. Moreover, knockdown TATDN1 also inhibited tumor growth and metastasis in a 95D mouse model in vivo by inhibiting B-catenin and Ezrin. These data indicate that TATDN1 expression is associated with 95D cells' higher potential of invasion and metastasis, and suggest that TATDN1 may be a potential prognostic factor and therapeutic target for NSCLCs |
| Pubmed ID | 26943769 |
| Year | 2016 |
| Title | The role and potential mechanisms of LncRNA-TATDN1 on metastasis and invasion of non-small cell lung cancer |
External Links
| Links for TATDN1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |